• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坦桑尼亚姆万扎未合并恶性疟原虫感染的间日疟患者采用青蒿琥酯-咯萘啶治疗时的无控制条件下的咯萘啶血药浓度。

Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.

机构信息

Department of Pharmacology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.

Department of Pharmacology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.

出版信息

Int J Infect Dis. 2022 Oct;123:192-199. doi: 10.1016/j.ijid.2022.08.020. Epub 2022 Sep 5.

DOI:10.1016/j.ijid.2022.08.020
PMID:36064162
Abstract

BACKGROUND

Therapeutic efficacy of artemether-lumefantrine is highly dependent on adequate systemic exposure to the partner drug lumefantrine particularly day 7 lumefantrine plasma concentration. There has been contradicting findings on the role of the cut-off values in predicting treatment outcomes among malaria patients in malaria endemic regions. This study assesses the day 3 and 7 lumefantrine plasma concentrations including related determinant factors and their influence on treatment outcomes among treated Tanzanian children and adults in uncontrolled conditions (real life condition).

METHODS

Data was nested from an efficacy study employing the WHO protocol, 2015 for monitoring antimalarial drug efficacy. Lumefantrine plasma concentration was measured by high performance liquid chromatography with ultraviolet (HPLC-UV).

RESULTS

Lumefantrine plasma concentrations below 175ng/ml and 200ng/ml on day 3 and 7 did not affect adequate clinical and parasitological response (ACPR) and recurrence of infection (p = 0.428 and 0.239 respectively). Age and baseline parasitemia were not associated to day 3 median lumefantrine plasma concentrations (p = 0.08 and 0.31 respectively) and day 7 lumefantrine plasma concentrations (p = 0.07 and 0.41 respectively). However, the day 3 and day 7 lumefantrine plasma concentrations were significantly higher in males compared to females (p = 0.03 and 0.042 respectively).

CONCLUSION

Lumefantrine plasma concentrations below cut-off points (175ng/ml and 200ng/ml) on day 3 and 7 did not influence treatment outcomes.

摘要

背景

青蒿琥酯-咯萘啶的治疗效果高度依赖于药物母体咯萘啶在体内的充分暴露,尤其是第 7 天的咯萘啶血药浓度。在疟疾流行地区,关于这些切点值在预测疟疾患者治疗结局中的作用,存在相互矛盾的研究结果。本研究评估了在未控制条件(真实生活条件)下,青蒿琥酯-咯萘啶治疗的坦桑尼亚儿童和成人的第 3 天和第 7 天的咯萘啶血药浓度及其相关决定因素,以及它们对治疗结局的影响。

方法

该数据是嵌套于一项 2015 年采用世界卫生组织(WHO)方案进行的抗疟药物疗效监测的疗效研究中。咯萘啶血药浓度采用高效液相色谱法-紫外检测(HPLC-UV)进行测定。

结果

第 3 天和第 7 天的咯萘啶血药浓度低于 175ng/ml 和 200ng/ml 并不会影响充分的临床和寄生虫学应答(ACPR)和感染复发(p 值分别为 0.428 和 0.239)。年龄和基线疟原虫密度与第 3 天的咯萘啶血药浓度中位数(p 值分别为 0.08 和 0.31)和第 7 天的咯萘啶血药浓度(p 值分别为 0.07 和 0.41)无关。然而,第 3 天和第 7 天的男性咯萘啶血药浓度明显高于女性(p 值分别为 0.03 和 0.042)。

结论

第 3 天和第 7 天的咯萘啶血药浓度低于切点值(175ng/ml 和 200ng/ml)并不影响治疗结局。

相似文献

1
Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.坦桑尼亚姆万扎未合并恶性疟原虫感染的间日疟患者采用青蒿琥酯-咯萘啶治疗时的无控制条件下的咯萘啶血药浓度。
Int J Infect Dis. 2022 Oct;123:192-199. doi: 10.1016/j.ijid.2022.08.020. Epub 2022 Sep 5.
2
Exploration of in vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in under fives in Tabora region, Tanzania.在坦桑尼亚塔波拉地区,探索蒿甲醚-本芴醇对五岁以下儿童无并发症恶性疟原虫疟疾的体内疗效。
Malar J. 2013 Feb 11;12:60. doi: 10.1186/1475-2875-12-60.
3
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.ART 在马拉维抗逆转录病毒治疗成人中的疗效。
Malar J. 2023 Jan 27;22(1):32. doi: 10.1186/s12936-023-04466-w.
4
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.甘帕拉肽(KAF156)联合青蒿琥酯固体分散体配方治疗无并发症恶性疟原虫疟疾:一项开放标签、多中心、平行组、随机、对照、2 期临床试验。
Lancet Infect Dis. 2023 Sep;23(9):1051-1061. doi: 10.1016/S1473-3099(23)00209-8. Epub 2023 Jun 13.
5
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.蒿甲醚-本芴醇治疗非复杂性恶性疟:一项使用个体患者数据对第7天本芴醇浓度和治疗反应进行的系统评价和荟萃分析。
BMC Med. 2015 Sep 18;13:227. doi: 10.1186/s12916-015-0456-7.
6
Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India.蒿甲醚-本芴醇治疗印度三个疟疾高发邦单纯性恶性疟的疗效
Malar J. 2016 Oct 13;15(1):498. doi: 10.1186/s12936-016-1555-4.
7
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.在坦桑尼亚,采用青蒿琥酯和咯萘啶联合疗法治疗无并发症恶性疟原虫疟疾患儿时,青蒿琥酯和咯萘啶的群体药代动力学和药效学。
Antimicrob Agents Chemother. 2010 Nov;54(11):4780-8. doi: 10.1128/AAC.00252-10. Epub 2010 Aug 16.
8
Persistence of Residual Submicroscopic P. falciparum Parasitemia following Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia.在埃塞俄比亚西部与苏丹接壤的边境地区,使用青蒿琥酯-咯萘啶治疗后,仍有残余的亚微观疟原虫寄生。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0000222. doi: 10.1128/aac.00002-22. Epub 2022 Aug 22.
9
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.吡喹酮-青蒿琥酯或双氢青蒿素-哌喹与当前一线疗法用于复发性无并发症疟疾的多次治疗:一项随机、多中心、开放标签、纵向、对照、3b/4 期试验。
Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29.
10
Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania.蒿甲醚-本芴醇治疗坦桑尼亚东北部非复杂性恶性疟的疗效与安全性
Malar J. 2014 Sep 20;13:376. doi: 10.1186/1475-2875-13-376.

引用本文的文献

1
Optimizing Lumefantrine Dosing for Young Children in High-Malaria-Burden Countries Using Pharmacokinetic-Pharmacodynamic Simulations.使用药代动力学-药效学模拟优化高疟疾负担国家幼儿的卤泛群给药方案。
Open Forum Infect Dis. 2024 Oct 17;11(11):ofae627. doi: 10.1093/ofid/ofae627. eCollection 2024 Nov.
2
The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A Systematic Review.细胞色素P450基因多态性对撒哈拉以南非洲疟疾患者药代动力学特征及治疗结果的影响:一项系统评价
Pharmgenomics Pers Med. 2023 May 18;16:449-461. doi: 10.2147/PGPM.S379945. eCollection 2023.
3
Merozoite Surface Proteins Polymorphisms and Treatment Outcomes among Patients with Uncomplicated Malaria in Mwanza, Tanzania.
坦桑尼亚姆万扎单纯性疟疾患者的裂殖子表面蛋白多态性与治疗结果
J Trop Med. 2022 Nov 23;2022:5089143. doi: 10.1155/2022/5089143. eCollection 2022.